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Abstract 
 
Introduction: The use of drugs to enhance recovery (‘rehabilitation pharmacology’) has been 
assessed. Amphetamine can improve outcome in experimental models of stroke, and several small 
clinical trials have assessed its use in stroke.  
 
Methods: Electronic searches were performed to identify randomised controlled trials of amphetamine 
in stroke (ischaemic or haemorrhagic). Outcomes included functional outcome (assessed as combined 
death or disability/dependency), safety (death) and haemodynamic measures. Data were analysed as 
dichotomous or continuous outcomes, using odds ratios (OR), weighted or standardised mean 
difference, (WMD or SMD) using random-effects models with 95% confidence intervals (95% CI); 
statistical heterogeneity was assessed. 
 
Results: Eleven completed trials (n=329) were identified. Treatment with amphetamine was 
associated with non-significant trends to increased death (OR 2.78 (95% CI, 0.75 to 10.23), n=329, 11 
trials) and improved motor scores (WMD 3.28 (95% CI -0.48 to 7.04) n=257, 9 trials) but had no effect 
on the combined outcome of death and dependency (OR 1.15 (95% CI 0.65 to 2.06, n=206, 5 trials). 
Amphetamine increased systolic blood pressure (WMD 9.3 mmHg, 95% CI 3.3 to 15.3, n=106 , 3 
trials) and heart rate (WMD 7.6 beats per minute, 95% CI 1.8 to 13.4, n=106, 3 trials). Despite 
variations in treatment regimes, outcomes and follow-up duration there was no evidence of significant 
heterogeneity or publication bias. 
 
Conclusion: No evidence exists at present to support the use of amphetamine after stroke. Despite a 
trend to improved motor function, doubts remain over safety and there are significant haemodynamic 
effects, the consequences of which are unknown. 
INTRODUCTION 
Stroke units save lives and, coupled with effective treatments such as thrombolysis and improved 
hyperacute care, more patients are surviving stroke. This, in the presence of an ageing population, 
has increased the number of stroke survivors, among whom the burden of stroke is high, with many 
patients left with significant disability. The brain’s ability to regenerate and undergo plastic change has 
long been exploited by rehabilitation; however, now the potential to exploit neuroplasticity with 
pharmacological agents seems to be a real possibility.
1, 2
 
 
Amphetamine, a sympathomimetic drug that leads to the release of noradrenaline and possibly 
dopamine and serotonin, acts as a stimulant, both centrally and peripherally.
3
 In experimental models 
of stroke, when given in conjunction with task specific practice, amphetamine has been shown to 
accelerate the recovery of motor function.
4-6
 Improved recovery is only seen when amphetamine is 
given with training related activity suggesting that in addition to modulation of central 
neurotransmitters, amphetamine may enhance long term potentiation. Further, amphetamine can 
result in neural sprouting and enhanced synaptogenesis 
7
 and augmentation of dendritic length and 
density, perhaps reflecting enhanced synaptic connectivity.
8
 
 
In healthy volunteers, amphetamine can modulate use dependent plasticity, as measured by task 
specific training performance and simultaneous transcranial magnetic stimulation evoked 
electromyographic responses.
9
 Similarly, in volunteers undergoing functional MRI, increased regional 
cerebral activation was seen, suggesting that amphetamine may lead to recruitment of neuronal units 
and/or increased activation within these units.
10
 
 
Several small trials have assessed the use of amphetamine after stroke and we sought to perform a 
systematic review to assess its effects on functional outcome and haemodynamic measures. 
 
METHODS 
 
Search strategy 
Electronic searches were performed in the Cochrane Stroke Group Trials Register (last searched June 
2008), Cochrane Controlled Trials Register (Cochrane Library, Issue 2, 2008), MEDLINE (1966-July 
2009), EMBASE (1980-June 2008), and Science Citation Index (1992-June 2008). The reference lists 
of all relevant articles and reviews were also checked to identify suitable studies. 
 
The following search strategy was used for MEDLINE and adapted for the other databases: 
1. Exp amphetamine 
2. ($amphetamine or amphetamine$ or d-amphetamine or dexamphetamine or dextroamphetamine or 
methamphetamine).tw  
3. (amphetam$).tw 
4. or/1-3 
5. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or 
exp carotid artery diseases/ or exp cerebrovascular accident/ or exp hypoxia-ischemia, brain/ or exp 
intracranial arterial diseases/ or intracranial arteriovenous malformations/ or exp "intracranial 
embolism and thrombosis"/ or exp intracranial hemorrhages/ or vasospasm, intracranial/ or vertebral 
artery dissection/ 
6. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or 
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or 
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. 
7. ((brain$ or cerebral or cerebell$ or intracranial or subarachnoid) adj5 (haemorrhage or hemorrhage 
or hematoma or haematoma or bleed$ or aneurysm)).tw. 
8. or/5-7 
9. 4 and 8 
10. limit 9 to human 
 
Data collection and analysis 
Randomised controlled trials of amphetamine in stroke (ischaemic or haemorrhagic) were selected for 
inclusion. Trial quality was assessed using standard criteria 
11
 including determining methods of 
randomisation, double blinding, participants lost to follow up, generation of random numbers, and 
allocation concealment. Data were independently extracted from publications, this including outcome 
measures (by intention-to-treat), ideally at end-of-treatment and at end-of-follow up. 
 
Types of outcome measures 
The primary outcome was functional outcome at end-of-follow up as assessed by combined death or 
disability/dependency, defined as a modified Rankin Scale (mRS) >2 or Barthel Index (BI) <60. 
Secondary outcomes included measures of impairment, function and haemodynamic measures, the 
latter including blood pressure (mmHg) and heart rate (beats per minute). 
 Data synthesis 
Data were analysed by 'intention-to-treat' where available, tested for heterogeneity using I2, and a 
weighted estimate calculated for the typical treatment effect across trials. Improvement scores were 
calculated, where possible, to assess change following treatment. Random effects models were used 
since between-trial sources of heterogeneity were expected, e.g. due to differences in type of 
treatment regime, outcome scales, and clinical and statistical differences between the trials. Treatment 
effects were determined using the odds ratio (OR) for dichotomous data and weighted mean 
difference (WMD) for continuous data, and 95% confidence intervals (CI) calculated. Where different 
assessment scales were being analysed (such as Fugl-Meyer and Rivermead Motor Assessment 
Scale) standardised mean difference (SMD) was calculated. The Cochrane Collaboration's Review 
Manager software, RevMan 4.2.7, was used for data entry and analysis. Publication bias was 
assessed visually using a funnel plot and statistically using Eggers plot. 
 
 
RESULTS 
 
Trials 
Eleven completed trials (329 patients) were identified and included in the analysis (figure 1). One 
ongoing trial was identified,
12
 and two trials had recently been terminated early due to problems 
recruiting patients.
13
 
14
 All but two trials limited inclusion to ischaemic stroke, and recruitment time 
ranged from within 72 hours to 6 weeks following stroke onset (table 1). Trial quality overall was good; 
one trial was single blind due to safety concerns, but all had blinded assessment of outcomes. Of the 
eleven trials, 2 are published only in abstract format.
15, 16
 A variety of outcome scales were used: 
motor impairment - Fugl-Meyer Scale (FMS), Rivermead Motor Assessment Scale or TEMPA test; 
neurological deficit - Scandinavian Stroke Scale (SSS); mood - Zung Depression score; and 
communication - Sheffield Screening test or Porch Communication Ability test. 
 
Death or disability/dependency 
The combined outcome of death or dependency was only reported in 5 trials (n=206 patients) and 
treatment with amphetamine did not alter it, OR 1.15 (95% CI 0.65 to 2.06) (figure 2). No change in 
disability (BI) was seen, WMD 0.12 (95% CI, -4.26-4.61). All 11 trials provided data on mortality and 
there was a trend for more deaths at the end of follow-up with amphetamine, OR 2.78 (95% CI, 0.75 to 
10.23) (figure 3). 
 
Impairment 
Motor impairment was the primary outcome in several trials and was recorded in 9 studies (n=257); a 
trend to better motor scores was present in patients treated with amphetamine, WMD 3.28 (95% CI -
0.48 to 7.04). Similarly, analysing change in motor scores from baseline to end-of-trial showed a trend 
to a better motor score improvement with amphetamine, SMD 0.28 (95% CI, -0.08 to 0.64) (figure 4). 
 
Neurological impairment was assessed in 2 studies (n=67 patients);
17, 18
 there were trends to better 
neurological score (SSS), WMD 2.43 (95% CI, -4.41 to 9.28), and greater change in score between 
baseline and end-of-treatment, WMD 3.96 (95% CI, -1.23 to 9.15) in the amphetamine group (figure 
9).
17, 18
 
 
Other outcomes 
Two studies analysed language,
19 18
 with no difference in language function as assessed by the Porch 
Communication Score or Sheffield screening score, SMD 0.11 (95% CI, -0.45 to 0.67). Language was 
the primary outcome in one of these studies 
19
 and, using a different method of analysis, a statistically 
significant improvement was seen in language ability. Mood, as assessed with the Zung depression 
score, did not improve in the amphetamine group, WMD 0.87 points (95% CI, -3.33 to 5.07), in the 2 
studies in which it was assessed.
15, 18
 
 
 
Haemodynamics 
Haemodynamic data was available in 3 studies (n=106 patients).
17, 18, 20
 Systolic and diastolic blood 
pressure both showed significant increases after dexamphetamine, WMD 9.29 (95% CI, 3.26 to 15.32) 
(figure 5) and WMD 5.13 (95% CI, 1.61 to 8.64) respectively. Heart rate was also significantly 
increased with amphetamine, WMD 7.61 (95% CI 1.78 to 13.43) (figure 6). 
 
Heterogeneity and publication bias 
Despite variations in treatment regimes, outcomes, and follow-up duration, there was no evidence of 
significant heterogeneity in any of the analyses. Additionally, there was no evidence of publication 
bias, either visually or statistically (p= 0.125). 
 
DISCUSSION 
Amphetamine was not associated with improvement in the combined outcome of death or dependency 
after stroke, in keeping with a previous smaller review
21
. Additionally, whilst there were trends to motor 
and neurological improvement, none of the effects were significant. Furthermore, there remains 
insufficient data to draw any conclusions regarding the effects of amphetamine on mood or 
communication or quality of life. This current analysis included data from newly published trials or data 
not previously available, doubling the available sample size in comparison to earlier review. 
21
 
 
There are many potential explanations for the lack of treatment effect seen. First, the varying outcome 
measures limited analysis and may have underestimated or concealed any potential effect. Wide 
confidence limits highlight the limited available data and make it difficult to draw firm conclusions. 
Similarly, many of the outcome measures demonstrate ceiling effects, although some studies 
excluded patients with mild weakness in an attempt to overcome this.
22-25
 Second, enrolment in a 
number of studies was completed early due to a low recruitment rate 
25
 
18
 so the intended sample size 
was not achieved thereby leading to a potential type II error. Difficulties recruiting into acute stroke 
trials with multiple exclusion criteria are well recognised.
26
 In two other studies, enrolment was 
terminated prematurely and the results remain unpublished. 
13, 14
 
 
Third, amphetamine may not be effective at improving outcome using the dose regimes tested in the 
available trials. The optimal treatment regime remains uncertain, with data from experimental stroke 
showing that a ‘bell-shaped’ dose response exists,
5
 i.e. both low and high doses, as well as early 
administration, are associated with a poor outcome.
4, 27
 In this respect, clinical trials tested lower and 
less frequent dosing than experimental models, presumably with the aim to reduce potential adverse 
effects.
4, 5, 28, 29
 
4, 27, 30
 Discrepancy between pre-clinical experiments and clinical trials is well 
documented in stroke studies and pre-clinical data needs rigorous assessment when utilised in the 
development of new treatments for stroke.
40
 
 
Fourth, it is feasible that baseline imbalances in stroke severity (with more severe stroke in the 
treatment group) may have concealed a treatment effect. This hypothesis is strengthened by the 
observation that the treatment effect appears to be greater when assessed in terms of improvement, 
thus taking into account any baseline imbalance. Unfortunately, limited sample sizes prevent 
stratification of data by prognostic baseline factors such as stroke syndrome, severity or time to 
recruitment. Similarly, no clinical study has taken into account the nature of ischaemic lesion, its size 
and location, which may help target interventions to selected groups of patients.
31
 
 
Fifth, significant haemodynamic effects may increase risk factors for a poor outcome with lack of 
treatment effect reflecting a balance between potential benefit and harm. Both elevations in blood 
pressure and heart rate are associated with poor outcome after stroke,
32
 
33
 as is impaired baroreceptor 
sensitivity, with increased cardiac events and arrhythmias.
34
 Despite this, the relationship between 
drug induced haemodynamic changes and outcome remains unclear. Experimental data supporting 
the use of amphetamine, where no tendency to harm has been demonstrated, have involved healthy 
volunteers. 
9, 35, 36
 This is in contrast to clinical studies where stroke patients are older and often have 
multiple co-morbidities. Similar to results utilising amphetamine in animal stroke models, data derived 
from the use of amphetamine in healthy volunteers needs cautious interpretation.  
 
Despite concerns regarding increasing heart rate and blood pressure, up to a fifth of acute stroke 
patients have low blood pressure, and hypotension is also associated with poor outcome. 
37
 Elevation 
of systemic blood pressure in the presence of dysfunctional cerebral autoregulation (as occurs in 
acute ischaemic stroke) might lead to augmentation in cerebral blood flow and, potentially, enhance 
recovery.
31
 Changes in cerebral blood flow with amphetamine have been demonstrated previously,
38
 
although these appeared to be region-specific and may represent cortical activation rather than 
systemic augmentation. Monitoring of treatment effects with functional imaging may provide further 
information on potential mechanisms of amphetamine action, as is being studied in normal 
volunteers.
39
 
 
Conclusions 
Despite a trend to improvement in motor scores, there is no evidence that amphetamines improve 
outcome in ischaemic stroke. Furthermore, there are significant haemodynamic effects, the 
consequences of which remain unclear but may have implications on prognosis. As such, doubt 
persists regarding the safety of amphetamine treatment. Further clinical trials are needed to further 
assess safety, and if appropriate, to define an optimal treatment regime.
21
 
Figure 1 Search strategy and selection process for identifying clinical trials of amphetamine in stroke 
 
Figure 2 Death and dependency by treatment group 
Figure 3 Death at end of trial by treatment group 
Figure 4 Improvement in motor score by treatment group 
Figure 5 Blood pressure by treatment group  
Figure 6 Heart rate by treatment group  
 
Table 1 Characteristics of included studies 
Author 
Date 
 
Subjects 
Control/ 
Active 
Dose regime Therapy 
intervention 
Type of patients Time 
post 
stroke 
Length of 
follow-up 
Primary outcome 
Crisostomo 
1988 
4/4 Single dose of 10 mg 
dexamphetamine 
45 mins physio 
session within 
3 hrs of 
treatment 
Ischaemic stroke 
with motor 
weakness 
Up to 10 
days 
3 days Motor (FM) 
Reding  
1995 
12/9 Dexamphetamine 10 
mg for 14 days then 
5mg/day for 3 days 
Standard in-
patient therapy 
Ischaemic stroke 
requiring 
rehabilitation 
7-45 
days 
3 weeks Motor (FM), Function 
(BI),  
Mood (ZDS) 
Walker-
Batson 
1995 
5/5 10 doses of 10 mg 
dexamphetamine at 
3-4 day intervals 
Physio session 
1 hour after 
treatment 
Ischaemic stroke 
with hemiplegia 
16-30 
days 
1 year Motor (FM), 
Sonde 
2001 
19/12 10 doses of 10 mg d,l-
amphetamine at 3-4 
day intervals 
30 mins physio 
1 hour after 
treatment 
Ischaemic and 
haemorrhagic 
stroke with 
paresis 
5-10 
days 
3 months Motor (FM), Function 
(BI) 
Vachalathiti 
2001 
14/13 10 mg 
metamphetamine for 
7 days 
Unknown Ischaemic stroke 0–10 
days 
3 weeks Motor (FM) 
Walker-
Batson 
9/12 10 doses of 10 mg 
dexamphetamine at 
1 hour speech 
therapy 45 
Ischaemic stroke 
with mod-severe 
16-45 
days 
6 months Communication 
(PICA) 
2001 3-4 day intervals mins after 
treatment 
aphasia 
Martinsson 
2003 
15/30 2.5-10 mg 
dexamphetamine 
twice daily for 5 days 
1 therapy 
session during 
the 5 day Rx 
period 
Ischaemic stroke 
motor weakness 
<72 
hours 
from 
onset 
90 days Safety (AE) 
Haemodynamics 
Neurological (SSS) 
Functional (BI) 
Treig 
2003 
12/12 10 doses of 10 mg 
dexamphetamine at 
3-4 day intervals 
Physio within 
60mins of 
treatment 
Ischaemic stroke 
with BI 0-50 
Up to 6 
weeks 
360 days Motor (RMAS), 
Function (BI) 
Platz 
2005 
13/18 10 doses of 10 mg d-
amphetamine at 3-4 
day intervals 
Therapy 2 
hours after 
dose 
Ischaemic stroke 
mild arm paresis 
3 weeks 
to 6 
months 
1 year Motor (TEMPA test 
time) 
Gladstone 
2006 
37/34 10 doses of 10 mg 
dexamphetamine at 
3-4 day intervals 
1 hour therapy 
session 90 
mins after 
dose 
Ischaemic or 
haemorrhagic 
stroke with mod-
severe 
hemiparesis 
5-10 
days 
3months Motor (FM), Function 
(BI) 
Sprigg 
2006 
16/17 Initial 5mg then 10 
doses of 10 mg 
dexamphetamine at 
3-4 day intervals 
Routine 
inpatient 
therapy 
Ischaemic stroke 
motor weakness 
3-30 
days 
90 days Motor (FM), 
Neurology (SSS), 
Function (BI, mRS), 
Haemodynamics (BP, 
HR, CBF) 
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